Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

was engaged in a research collaboration with Merck & Co., Inc. (Merck). Prior to ev3's acquisition of FoxHollow, ev3 did not recognize any research collaboration revenue. This research collaboration was terminated by Merck effective in July 2008. ev3's management believes that in order to properly understand underlying business trends in and performance of ev3's ongoing operations, management has found and investors may find it useful to consider the impact of excluding research collaboration revenue from ev3's total net sales.

-- Research collaboration asset impairment. As a result of the termination of ev3's research collaboration with Merck, ev3 recorded an asset impairment charge of $10.5 million during the second quarter 2008 to write-off the remaining carrying value of the related Merck intangible asset that was established at the time of ev3's acquisition of FoxHollow. In addition to disclosing net income that is determined in accordance with GAAP, ev3's management believes that in order to properly understand the underlying business trends and performance of ev3's ongoing operations, management has found and investors may find it useful to consider the impact of excluding the $10.5 million research collaboration asset impairment charge recorded by ev3 in second quarter 2008.

-- Non-cash stock-based compensation. ev3 excludes stock-based compensation expense from its non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring expense, is not an expense that requires cash settlement and is not used by ev3's management to assess the core profitability of ev3's business operations. ev3's management also believes that excluding this item from ev3's non-GAAP results is useful to investors to understand the application of SFAS 123R and its impact on ev3's operational performance, liquidity and its ability to invest in research and development and fund acquisitions and capital expenditures and it allows for g
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... The National Necrotizing Fasciitis Foundation ... by doctors at Vanderbilt University Hospital in ... and Dr. John Crew , director of the ... Center in Daly City, CA. ... pioneered by Dr. Crew, that had previously saved the ...
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended June ... in Canadian dollars and presented under International Financial ... activities with respect to our Oral Amp B ... contract manufacturer," said Andrew Rae , President ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Reportlinker.com announces that a new market research ... Established and Emerging Biotech Clusters ... There has been widespread interest ... companies and related organizations. It is important ...
... Keryx Biopharmaceuticals (Nasdaq: KERX ) today ... component of its Phase 3 registration program of Zerenex™, ... of elevated serum phosphorus levels, or hyperphosphatemia, in patients ... Phase 3 registration program, which is being conducted pursuant ...
... The ALS Therapy Development Institute (ALS TDI) and ... their current research collaboration agreement to test additional ... stop the progression of Amyotrophic Lateral Sclerosis (ALS, ... collaboration is based on encouraging results from early-stage ...
Cached Biology Technology:Established and Emerging Biotech Clusters 2Established and Emerging Biotech Clusters 3Established and Emerging Biotech Clusters 4Established and Emerging Biotech Clusters 5Established and Emerging Biotech Clusters 6Established and Emerging Biotech Clusters 7Established and Emerging Biotech Clusters 8Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 2ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies 3
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... that one of the cell's largest families of signaling ... development of nerve cells, also controls nerve cells' ability ... memory. These findings, the first to link these molecular ... the May issue of Nature Cell Biology, published in ...
... of BioModels, the world's first database of annotated ... collaboration led by the European Bioinformatics Institute (UK) ... develops open-source standards to describe biological systems. Other ... Systems Biology Institute (Japan) and Stellenbosch University (South ...
... of medical scientists has made an important advance in ... cancer in the industrialized world. Professor Jeremy R. Jass, ... at McGill University in Montreal, and colleagues in Australia ... cancer can be inherited. The new syndrome is characterized ...
Cached Biology News:Structure-building cell signals also may influence learning and memory 2Structure-building cell signals also may influence learning and memory 3A new way to share models of biological systems 2Important discovery about second most fatal cancer 2
... For separation and ... Efficient separation of nuclei from ... in sample complexity, greatly facilitating ... Subfractionation of nucleic acid binding ...
... of Eagle's medium have been ... The most widely used modification ... is a modification of Minimum ... contains a higher concentration of ...
... The EpiTect Bisulfite Kit enables ... uracils in less than 6 hours. ... innovative protection against DNA degradation and ... to guarantee fast and reliable results ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
Biology Products: